Thane

NORTH AMERICAN SPECIALTY LAMINATIONS ("NASL") ACQUIRES DIVERSIFIED MANUFACTURING OF CALIFORNIA ("DMOC"), EXPANDING NASL'S PROFILE LAMINATION CAPACITY, AND ESTABLISHING ITS COAST-TO-COAST FOOTPRINT

Retrieved on: 
Thursday, March 23, 2023
Senior, Vista, River, NASL, Intrinsic and extrinsic properties, Acquisition, Growth, Heartland Industrial Partners, OEM, Transport, Holland & Knight, Thane, Diversification, Engineered wood

OSSEO, Wis., March 23, 2023 /PRNewswire/ -- North American Specialty Laminations ("NASL"), the leading provider of differentiated specialty lamination, fabrication, and finishing solutions to the building products OEM industry, today announced its acquisition of Diversified Manufacturing of California ("DMOC") dba, Profile Wrapping; (https://profilewrapping.com) - a West Coast-based profile lamination wrapping specialist.  NASL serves customers in the window, door, flooring, specialty millwork, cabinetry, and case-goods markets.  It is backed by Building Industry Partners ("BIP"), the leading private equity firm focused on the U.S. building industry.

Key Points: 
  • It is backed by Building Industry Partners ("BIP"), the leading private equity firm focused on the U.S. building industry.
  • With recessionary and near-term housing market headwinds, capital investment costs, labor constraints and rising transportation costs pose major obstacles in the market.
  • DMOC's expertise will immediately augment NASL's lamination capabilities and capacity, particularly for color products in the window and door markets.
  • DMOC's employees hold an average of 15 years of lamination experience, and NASL plans to retain all of them.

Solarea Bio Investigators Receive National Academy of Medicine Healthy Longevity 2022 Quickfire Challenge Award

Retrieved on: 
Thursday, September 29, 2022
Disability, Probiotic, Health, Inflammation, National academy, Agriculture, Ageing, Database, Longevity, Mycobiome, Disease, Research, Johnson & Johnson, Alzheimer's disease, Solera, United Nations, National Academy of Medicine, Population, Farmers' Market Nutrition Program / Senior Farmers' Market Nutrition Program, Degenerative disease, Moon, DRS, Thane, Translational research, Hinda, CEO, Solution, Bacteria, Cardiovascular disease, Fungus, Collection, CJE SeniorLife, Harvard Medical School, Data science, Multimedia, NAM, Immune system, Vegetable, Pharmaceutical industry, Dentistry, Dietary supplement, Atlantic Ocean

CAMBRIDGE, Mass., Sept. 29, 2022 /PRNewswire/ -- Solarea Bio, a clinical stage biotech company, has been selected as an awardee of the NAM Healthy Longevity 2022 QuickFire Challenge, launched by Johnson & Johnson Innovation together with the National Academy of Medicine, for work studying the mycobiome as a novel class of probiotics to target inflammation associated with aging, or 'inflammaging'.  

Key Points: 
  • CAMBRIDGE, Mass., Sept. 29, 2022 /PRNewswire/ -- Solarea Bio , a clinical stage biotech company, has been selected as an awardee of the NAM Healthy Longevity 2022 QuickFire Challenge, launched by Johnson & Johnson Innovation together with the National Academy of Medicine, for work studying the mycobiome as a novel class of probiotics to target inflammation associated with aging, or 'inflammaging'.
  • With inflammation as its core target, Solarea is developing a pipeline of products in addition to its existing lead clinical program for the dietary management of bone health.
  • Dr. Eric Schott, co-founder and Vice President of Translational Research and Operations at Solarea said, "Healthy aging as a target is advancing through the product development process with strong initial results.
  • The National Academy of Medicine's Healthy Longevity Initiative is designed to kick start innovation to support healthy longevity through a series of monetary awards and prizes.

BIORCHESTRA appointed Dr. Gabriel Helmlinger (Ph.D., DABT) as Head of Translational and Clinical Pharmacology, Toxicology

Retrieved on: 
Tuesday, August 23, 2022
Obsidian, AstraZeneca, Harvard Medical School, Massachusetts General Hospital, Novartis, J&J, CEO, RNA, Pharmacokinetics, Multiple sclerosis, Georgia Institute of Technology College of Computing, Lists of diseases, American Board of Commissioners for Foreign Missions, Acid, Master of Science, Therapy, Administration, Peptide, Universitate metro station, Human back, Lead, Radiation therapy, Innovation, Organization, Traffic barrier, Alzheimer's disease, Biomedical engineering, Sirna, Antibody, Parkinson, Probability, Pharmacology, KRW, Hospital, Thane, Neurodegeneration, Biomarker, Business, RNA transfection, ALS, Drug development, Bachelor of Engineering, ASO, Pharmaceutical industry, Research, Toxicology, Alfred Compigne, Epilepsy, Neuroscience, Translation

BOSTON, Mass., Aug. 23, 2022 /PRNewswire/ -- BIORCHESTRA, headquartered in Daejeon, South Korea, appointed Dr. Gabriel Helmlinger (Ph.D., D.A.B.T.)

Key Points: 
  • BOSTON, Mass., Aug. 23, 2022 /PRNewswire/ -- BIORCHESTRA, headquartered in Daejeon, South Korea, appointed Dr. Gabriel Helmlinger (Ph.D., D.A.B.T.)
  • as Vice-President, Head of Translational & Clinical Pharmacology, Toxicology.
  • Dr. Helmlinger brings 25 years of drug research and clinical development experience in the biotech and global pharmaceutical industries.
  • O'Dea, a founding member of Moderna, was appointed as Chief Medical Officer of BIORCHESTRA, President of BIORCHESTRA US.

ENHANC3D GENOMICS Awarded QuickFire Challenge Grant

Retrieved on: 
Thursday, May 26, 2022
Lists of diseases, DNA, Babraham Institute, Genome, Company, Disease, Research, Coronary heart disease, susceptibility to, 8, Multiomics, Challenge, Science, VC, Patient, Solution, Health, UK Research and Innovation, Thane, Institute, BBSRC, Neurodegeneration, Mentorship, Industry, Genetic code, Life, Genomics, Biomarker, Technology, Biotechnology, Biotechnology and Biological Sciences Research Council, Maintenance, Precision medicine, Biology, 3D, Family, Innovation, Pharmaceutical industry, Antibiotics, Financial services, Medical imaging, EU

CAMBRIDGE, England, May 26, 2022 /PRNewswire/ -- ENHANC3D GENOMICS ("Enhanc3D"), a biotechnology company unlocking the full potential of the human 3D genome to accelerate patient-centric medicine, announces it has been selected as one of the awardees under Johnson & Johnson Innovation's Immunology Innovations QuickFire Challenge .

Key Points: 
  • CAMBRIDGE, England, May 26, 2022 /PRNewswire/ -- ENHANC3D GENOMICS ("Enhanc3D"), a biotechnology company unlocking the full potential of the human 3D genome to accelerate patient-centric medicine, announces it has been selected as one of the awardees under Johnson & Johnson Innovation's Immunology Innovations QuickFire Challenge .
  • Debora Lucarelli, Chief Executive Officer of Enhanc3D Genomics, commented: "Our vision is to leverage the human 3D genome and state-of-the-art analytics of our platform GenLink3DTMto enable breakthroughs in precision medicine.
  • We invested in Enhanc3D with a strong belief that GenLink3DTM will revolutionise patient centric medicine as a first-in-class 3D genomics navigator.
  • ENHANC3D GENOMICS ("Enhanc3D") is a private functional genomics company based in Cambridge, UK which was founded in 2020 out of Professor Peter Fraser's pioneering 3D genome organisation research laboratory at the Babraham Institute.

ENHANC3D GENOMICS Awarded QuickFire Challenge Grant

Retrieved on: 
Thursday, May 26, 2022
Lists of diseases, DNA, Babraham Institute, Genome, Company, Disease, Research, Coronary heart disease, susceptibility to, 8, Multiomics, Challenge, Science, VC, Patient, Solution, Health, UK Research and Innovation, Thane, Institute, BBSRC, Neurodegeneration, Mentorship, Industry, Genetic code, Life, Genomics, Biomarker, Technology, Biotechnology, Biotechnology and Biological Sciences Research Council, Maintenance, Precision medicine, Biology, 3D, Family, Innovation, Pharmaceutical industry, Antibiotics, Financial services, Medical imaging, EU

CAMBRIDGE, England, May 26, 2022 /PRNewswire/ -- ENHANC3D GENOMICS ("Enhanc3D"), a biotechnology company unlocking the full potential of the human 3D genome to accelerate patient-centric medicine, announces it has been selected as one of the awardees under Johnson & Johnson Innovation's Immunology Innovations QuickFire Challenge .

Key Points: 
  • CAMBRIDGE, England, May 26, 2022 /PRNewswire/ -- ENHANC3D GENOMICS ("Enhanc3D"), a biotechnology company unlocking the full potential of the human 3D genome to accelerate patient-centric medicine, announces it has been selected as one of the awardees under Johnson & Johnson Innovation's Immunology Innovations QuickFire Challenge .
  • Debora Lucarelli, Chief Executive Officer of Enhanc3D Genomics, commented: "Our vision is to leverage the human 3D genome and state-of-the-art analytics of our platform GenLink3DTMto enable breakthroughs in precision medicine.
  • We invested in Enhanc3D with a strong belief that GenLink3DTM will revolutionise patient centric medicine as a first-in-class 3D genomics navigator.
  • ENHANC3D GENOMICS ("Enhanc3D") is a private functional genomics company based in Cambridge, UK which was founded in 2020 out of Professor Peter Fraser's pioneering 3D genome organisation research laboratory at the Babraham Institute.

IndyGeneUS AI Awarded Grant Funding through QuickFire Challenge

Retrieved on: 
Thursday, May 12, 2022
Retinitis pigmentosa, Harwell Science and Innovation Campus, DNA, EHR, Disease, Johnson & Johnson, Army of the United States, Woman, Biology, Veterans Endeavor for Treatment and Support (VETS) Court, Health, Degenerative disease, Thane, Child, Service-Disabled Veteran-Owned Small Business, SDVOSB, Veteran, National, Walter Reed Army Medical Center, Whole genome sequencing, Man, Biomarker, Genomics, Therapy, Health equity, Black–brown unity, Management, Medical device

WASHINGTON, May 12, 2022 /PRNewswire/ -- Today, IndyGeneUS AI was named an awardee of the Johnson & Johnson Innovation Veterans Lead QuickFire Challenge: Innovations by Vets.

Key Points: 
  • WASHINGTON, May 12, 2022 /PRNewswire/ -- Today, IndyGeneUS AI was named an awardee of the Johnson & Johnson Innovation Veterans Lead QuickFire Challenge: Innovations by Vets .
  • IndyGeneUS AI is a precision genomics company aiming to create the world's largest blockchain-encrypted digital health platform of indigenous and diasporic African clinical and genomic data.
  • "This is literally a dream come true, and a bit nostalgic," said IndyGeneUS AI Founder, Yusuf Henriques.
  • In addition to being awarded the QuickFire Challenge, IndyGeneUS AI officially became a resident at JLABS @ Washington, DC on May 1st.

Envoy Global Expands Leadership Team, Appoints New Interim President of Global Immigration, Chief Compliance & Privacy Officer, General Counsel and Head of DEI

Retrieved on: 
Tuesday, January 18, 2022
DEI, GAIN Capital, Compliance, Chambers, Thane, Technology, Eura, Hope, Organization, Negotiation, Kraft Foods Inc., Growth, Equity, CEO, StoneX Group Inc., Leadership, CIP, GIA, JD, Industry, Goal, Consultant, Privacy, Community, ITA, Efficiency, Multimedia, Workforce, Chief, General counsel, Risk, P.C, Interim, Private law, HR, Kraft Foods, Practice of law, Private practice, Sex industry, Toy, Management

Sophy King has joined the company as Interim President, Global Immigration, along with Lara Thane, JD, General Counsel, Chief Compliance & Privacy Officer and Sharon Ray, Head of Diversity, Equity and Inclusion (DEI).

Key Points: 
  • Sophy King has joined the company as Interim President, Global Immigration, along with Lara Thane, JD, General Counsel, Chief Compliance & Privacy Officer and Sharon Ray, Head of Diversity, Equity and Inclusion (DEI).
  • Sophy King, Envoy Global's new Interim President, Global Immigration, has two decades of experience in immigration.
  • King began her career at Emigra, working as an assistant immigration consultant before ending up as their Director for Consulting and Compliance.
  • Also reporting to President & CEO Dick Burke, Lara Thane serves as a primary legal advisor to Envoy Global, overseeing all legal, compliance and privacy matters.

BIORCHESTRA appoints pharma veteran and Moderna and Akcea (Ionis) CMO "Dr. Louis St. L. O'Dea" as CMO of BIORCHESTRA

Retrieved on: 
Thursday, September 23, 2021
Therapy, Neurodegeneration, Exosome, Data management, Anders (singer), Degenerative disease, NCE, McGill University, Shanda, Growth, Pharmacology, Faculty, Statistics, FRCP, Investment, Industry, EMA, Protein, Travel, 2021 Essex County Council election, Traffic barrier, Alzheimer's disease, Alexion, BCH, Primate, University College Dublin, Defense Advanced GPS Receiver, Peptide, RNA transfection, RNA, NASDAQ, BAO, Harvard University, Thane, CMO, AstraZeneca, Johnson & Johnson, McGill, Patent, MB, Patient, Board, ANDA, Head, ALS, Research, Drug development, US, Pharmaceutical industry, Fine chemical

In addition, their proprietary exosome-based diagnostic that detects and quantifies markers of neuroinflammation and neurodegeneration facilitates patient selection and treatment monitoring.

Key Points: 
  • In addition, their proprietary exosome-based diagnostic that detects and quantifies markers of neuroinflammation and neurodegeneration facilitates patient selection and treatment monitoring.
  • BIORCHESTRA has been recently recognized for its achievements by Johnson & Johnson in their Innovation QuickFire Challenge in Neuroscience in June, 2021.
  • [i][ii]
    Reflecting the success of its research and development programs and anticipating its international expansion and entry into clinical development, the BIORCHESTRA has appointed Dr. Louis St.L.
  • O'Dea (MB, BCh, BAO, FRCP has worked as CMO in global pharmaceutical companies such as Serono, Moderna, Akcea (Ionis), Radius and Oxford Immunotec for 28 years.

Gatekeeper Innovation Inc Named QuickFire Challenge Awardee

Retrieved on: 
Thursday, August 26, 2021
Medicine, Johnson & Johnson, Friends, Program, Technology, Family, Children's Medical Safety Research Institute, Time, Patient advocacy, Multimedia, Gatekeeper, Thane, Adult, Science, Solution, CEO, View, Company, Pharmaceutical industry, Birth control

SACRAMENTO, Calif., Aug. 26, 2021 /PRNewswire/ --Johnson & Johnson Innovation named Gatekeeper Innovation Inc. the awardee in the Pill Protect QuickFire Challenge: Designing for Medication Safety.

Key Points: 
  • SACRAMENTO, Calif., Aug. 26, 2021 /PRNewswire/ --Johnson & Johnson Innovation named Gatekeeper Innovation Inc. the awardee in the Pill Protect QuickFire Challenge: Designing for Medication Safety.
  • Gatekeeper answered the call with two redesigned child-resistant pill minders for potentially safer medication storage in the home.
  • As an awardee of the challenge, Gatekeeper has received $100,000 in grant funding, access to the global Johnson & Johnson Innovation - JLABS network, and mentorship from experts across the Johnson & Johnson Family of Companies.
  • About Gatekeeper Innovation Inc: Gatekeeper is a Sacramento-based manufacturing and technology company offering tamper-evident, abuse-deterrent solutions while supporting medication adherence.